Nanocatalyst Complex Can Dephosphorylate Key Proteins in MAPK Pathway for Cancer Therapy

Abstract Controlling phosphorylation processes of proteins is a facile way for manipulating cell fates. Herein, a synergistic therapeutic strategy utilizing a near‐infrared (NIR)‐responsive nanocatalyst (NC) complex is presented, which is comprised of photoactive NC and protein phosphatase 2A (PP2A), to synergistically inhibit hyperphosphorylation of mitogen‐activated protein kinase (MAPK) pathway for cancer therapy, as an example of many biological processes this approach can apply to. NIR‐triggered release of PP2A specially dephosphorylates and inactivates mitogen‐activated protein kinase kinase (MAP2K, also known as MEK) and extracellular regulated protein kinases (ERK) in the MAPK pathway, meanwhile, the NIR‐triggered activation of NC decreases the level of intracellular adenosine triphosphate to attenuate protein phosphorylation of MEK and ERK. The synergistic therapeutics effectively suppress melanoma progression by inhibiting hyperphosphorylation of the MAPK pathway. In addition, the nanocatalyst complex reduces the risk of drug‐resistance through inhibiting a rebound of RAS‐GTP. The NIR‐responsive nanocatalyst complex paves a novel way for cancer therapeutics.